These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 17565634)

  • 1. Effect of esomeprazole and rabeprazole on intragastric pH in healthy Chinese: an open, randomized crossover trial.
    Li ZS; Zhan XB; Xu GM; Cheng NN; Liao Z
    J Gastroenterol Hepatol; 2007 Jun; 22(6):815-20. PubMed ID: 17565634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intragastric acidity after switching from 5-day treatment with intravenous pantoprazole 40 mg/d to 5-day treatment with oral esomeprazole 40 mg/d or pantoprazole 40 mg/d: an open-label crossover study in healthy adult volunteers.
    Miner PB; Tutuian R; Castell DO; Liu S; Sostek MB
    Clin Ther; 2006 May; 28(5):725-33. PubMed ID: 16861094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An open-label, parallel, multiple-dose study comparing the pharmacokinetics and gastric acid suppression of rabeprazole extended-release with esomeprazole 40 mg and rabeprazole delayed-release 20 mg in healthy volunteers.
    Morelli G; Chen H; Rossiter G; Rege B; Lu Y
    Aliment Pharmacol Ther; 2011 Apr; 33(7):845-54. PubMed ID: 21272047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
    Miner P; Katz PO; Chen Y; Sostek M
    Am J Gastroenterol; 2003 Dec; 98(12):2616-20. PubMed ID: 14687806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of intravenous esomeprazole 40 mg and pantoprazole 40 mg on intragastric pH in healthy subjects. A prospective, open, randomised, two-way cross-over comparative study.
    Piccoli F; Ory G; Hadengue A; Beglinger C; Degen L
    Arzneimittelforschung; 2007; 57(10):654-8. PubMed ID: 18074759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intragastric acid control in non-steroidal anti-inflammatory drug users: comparison of esomeprazole, lansoprazole and pantoprazole.
    Goldstein JL; Miner PB; Schlesinger PK; Liu S; Silberg DG
    Aliment Pharmacol Ther; 2006 Apr; 23(8):1189-96. PubMed ID: 16611280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily--a randomized, two-way crossover study.
    Miehlke S; Madisch A; Kirsch C; Lindner F; Kuhlisch E; Laass M; Knoth H; Morgner A; Labenz J
    Aliment Pharmacol Ther; 2005 Apr; 21(8):963-7. PubMed ID: 15813831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of the area under the plasma concentration vs time curve and the maximum plasma concentration of esomeprazole on intragastric pH.
    Junghard O; Hassan-Alin M; Hasselgren G
    Eur J Clin Pharmacol; 2002 Oct; 58(7):453-8. PubMed ID: 12389067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acid control with esomeprazole and lansoprazole: a comparative dose-response study.
    Wilder-Smith C; Lind T; Lundin C; Nauclér E; Nilsson-Pieschl C; Röhss K
    Scand J Gastroenterol; 2007 Feb; 42(2):157-64. PubMed ID: 17327934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of intravenous application of esomeprazole 40 mg versus pantoprazole 40 mg on 24-hour intragastric pH in healthy adults.
    Hartmann D; Eickhoff A; Damian U; Riemann JF; Schilling D
    Eur J Gastroenterol Hepatol; 2007 Feb; 19(2):133-7. PubMed ID: 17272998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjects.
    Warrington S; Baisley K; Boyce M; Tejura B; Morocutti A; Miller N
    Aliment Pharmacol Ther; 2002 Jul; 16(7):1301-7. PubMed ID: 12144580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of esomeprazole and lansoprazole for control of intragastric pH in patients with symptoms of gastro-oesophageal reflux disease.
    Johnson DA; Stacy T; Ryan M; Wootton T; Willis J; Hornbuckle K; Brooks W; Doviak M
    Aliment Pharmacol Ther; 2005 Jul; 22(2):129-34. PubMed ID: 16011671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect on intragastric pH of a PPI with a prolonged plasma half-life: comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteers.
    Hunt RH; Armstrong D; James C; Chowdhury SK; Yuan Y; Fiorentini P; Taccoen A; Cohen P
    Am J Gastroenterol; 2005 Sep; 100(9):1949-56. PubMed ID: 16128938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
    Röhss K; Lind T; Wilder-Smith C
    Eur J Clin Pharmacol; 2004 Oct; 60(8):531-9. PubMed ID: 15349707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of low-dose rabeprazole and omeprazole on gastric acidity: results of a double blind, randomized, placebo-controlled, three-way crossover study in healthy subjects.
    Bruley des Varannes S; Gharib H; Bicheler V; Bost R; Bonaz B; Stanescu L; Delchier JC; Bonnot-Marlier S
    Aliment Pharmacol Ther; 2004 Oct; 20(8):899-907. PubMed ID: 15479362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined analysis of three crossover clinical pharmacology studies of effects of rabeprazole and esomeprazole on 24-h intragastric pH in healthy volunteers.
    Norris V; Baisley K; Dunn K; Warrington S; Morocutti A
    Aliment Pharmacol Ther; 2007 Feb; 25(4):501-10. PubMed ID: 17270006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects.
    Williams MP; Sercombe J; Hamilton MI; Pounder RE
    Aliment Pharmacol Ther; 1998 Nov; 12(11):1079-89. PubMed ID: 9845397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Esomeprazole 40 mg provides improved intragastric acid control as compared with lansoprazole 30 mg and rabeprazole 20 mg in healthy volunteers.
    Wilder-Smith CH; Röhss K; Nilsson-Pieschl C; Junghard O; Nyman L
    Digestion; 2003; 68(4):184-8. PubMed ID: 14691345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers.
    Saitoh T; Fukushima Y; Otsuka H; Hirakawa J; Mori H; Asano T; Ishikawa T; Katsube T; Ogawa K; Ohkawa S
    Aliment Pharmacol Ther; 2002 Oct; 16(10):1811-7. PubMed ID: 12269976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral rabeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric pH in healthy subjects.
    Armstrong D; James C; Camacho F; Chen Y; Horbay GL; Teixeira B; Husein-Bhabha FA
    Aliment Pharmacol Ther; 2007 Jan; 25(2):185-96. PubMed ID: 17116123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.